Opko Health, Inc. (OPK) Given "Buy" Rating at Laidlaw

10/10/2016 - Opko Health Inc had its "perform" rating reiterated by analysts at Oppenheimer.

OPKO Health, Inc (OPKO) is a healthcare company. In the past 52 weeks, the share price moved between $7.12 and $12.15.

Over the period of 6 months, Insider Purchases show a total of 70 transaction in which 2289980 shares were traded.

Rhumbline Advisers reported 330,221 shares or 0.01% of all its holdings. (NASDAQ:OPK) traded with the volume of 9.56 Million in the previous trading session.

Stock has got outperform rating from 5 analysts of Thomson Reuters whereas 5 analysts given hold rating to the stock. Stock Is Sinking Today" on December 30, 2016, also Marketwatch.com with their article: "Opko Health reports disappointing results in late-stage trial of human growth." published on December 30, 2016, Profitconfidential.com published: "Opko Health Inc.: "This Medicine Is Killing OPK Stock" on December 31, 2016. Zacks Investment Research gave Opko Health, Inc.

According to Yahoo Finance, the price target for the company which analysts are aiming is 19.5. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $30,382,614.90. The debt-to-equity ratio (D/E) remains 0.04. (NASDAQ:OPK) declined -2.26% to $9.09.

The company's stock now has 6.37 Billion in market capitalization. (NASDAQ:OPK) where Standpoint Research provided Buy rating on the stock on 3-Jun-16. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. TheStreet downgraded Opko Health from a "hold" rating to a "sell" rating in a report on Wednesday, November 9th.

According to sentiments of 5 analysts the company is expected to report revenues of $310.82M for the current quarter. Analyst's mean target price for the firm is $51.29 while analysts mean recommendation is 1.90.

On 11/30/2016 Phillip Md Et Al Frost, CEO, bought 1,800 with an average share price of $10.40 per share and the total transaction amounting to $18,720.00. For the Current Quarter, 2 analysts are projecting the mean EPS to be $-0.01/share. During the same period past year, the company earned $0.25 earnings per share.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of US and global copyright and trademark legislation. Price T Rowe Associates Inc. Bank of New York Mellon Corp boosted its position in shares of Opko Health by 3.7% in the second quarter. MD now owns 947,871 shares of the company's stock valued at $10,038,000 after buying an additional 28,700 shares in the last quarter. MD raised its position in shares of Opko Health by 3.1% in the third quarter. LPL Financial LLC now owns 13,374 shares of the company's stock valued at $142,000 after buying an additional 504 shares in the last quarter. Finally, Jaffetilchin Investment Partners LLC boosted its position in shares of Opko Health by 1.2% in the second quarter. Fund Management has invested 0.01% of its portfolio in Opko Health Inc. The Firm operates through two divisions: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations.



Latest news

Other news